KELLY BRAZZLE: Open Payments
NPI 1912331893 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$214 in 11 payments from 9 companies in 2025. Trend: 2023 $131 · 2024 $156 · 2025 $214
Food & beverage: $214
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 2 | $40 |
| Merck Sharp & Dohme LLC | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $28 |
| GlaxoSmithKline, LLC. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Novartis Pharmaceuticals Corporation | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Incyte Corporation | 1 | $17 |
Products named: VENCLEXTA, KEYTRUDA, Enhertu, JEMPERLI, ICLUSIG, KISQALI, LYNPARZA, Onivyde.
Industry payments across MO — which companies pay providers there.
